OBJECTIVE: The aim of the project was to assess the effectiveness and safety of weekly epoetin-beta (EB) in patients with gastrointestinal cancer (GIC) subjected to concomitant chemoradiotherapy (CCTRT). METHODS: In this clinical prospective and multicentre cohort study EB was administered at a dose of 30,000 IU/ week, during CCTRT and in the four weeks thereafter, and suspended if haemoglobin (Hb) increased >2 g/dl or Hb >12-13 g/dl. Effectiveness was defi ned as Hb increase ≥1 g/dl vs. baseline. Time to response, treatment toxicity and transfusion requirements were also assessed. RESULTS: EB was effective in 75.8% of the evaluable population within a median of four weeks from EB initiation, without blood transfusions. Over 80% of all patients remained below the threshold (Hb ≤13 g/dl) and no study drug-related adverse reactions were recorded. CONCLUSION: Weekly EB proved to be effective and well tolerated by patients with GIC subjected to CCTRT.
OBJECTIVE: The aim of the project was to assess the effectiveness and safety of weekly epoetin-beta (EB) in patients with gastrointestinal cancer (GIC) subjected to concomitant chemoradiotherapy (CCTRT). METHODS: In this clinical prospective and multicentre cohort study EB was administered at a dose of 30,000 IU/ week, during CCTRT and in the four weeks thereafter, and suspended if haemoglobin (Hb) increased >2 g/dl or Hb >12-13 g/dl. Effectiveness was defi ned as Hb increase ≥1 g/dl vs. baseline. Time to response, treatment toxicity and transfusion requirements were also assessed. RESULTS: EB was effective in 75.8% of the evaluable population within a median of four weeks from EB initiation, without blood transfusions. Over 80% of all patients remained below the threshold (Hb ≤13 g/dl) and no study drug-related adverse reactions were recorded. CONCLUSION: Weekly EB proved to be effective and well tolerated by patients with GIC subjected to CCTRT.
Authors: Matti S Aapro; Gunnar Birgegård; Carsten Bokemeyer; Paul Cornes; Jan Foubert; Pere Gascon; John Glaspy; Eva Hellström-Lindberg; Hartmut Link; Heinz Ludwig; Anders Osterborg; Lazzaro Repetto; Pierre Soubeyran Journal: Lancet Oncol Date: 2008-05 Impact factor: 41.316
Authors: C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran Journal: Eur J Cancer Date: 2006-12-19 Impact factor: 9.162
Authors: Peter J Barrett-Lee; Heinz Ludwig; Gunnar Birgegård; Carsten Bokemeyer; Pere Gascón; Paris A Kosmidis; Maciej Krzakowski; Johan W R Nortier; Gail Kongable; Maurice Schneider; Dirk Schrijvers; Simon J Van Belle Journal: Oncology Date: 2006-02-21 Impact factor: 2.935
Authors: H-G Strauss; G Haensgen; J Dunst; C R W Hayward; H-U Burger; A Scherhag; H Koelbl Journal: Int J Gynecol Cancer Date: 2007-07-21 Impact factor: 3.437
Authors: Jean-Loup Mouysset; Beata Freier; Joan van den Bosch; Charles Briac Levaché; Alain Bols; Hans Werner Tessen; Laura Belton; G Chet Bohac; Jan-Henrik Terwey; Giuseppe Tonini Journal: Cancer Manag Res Date: 2016-01-21 Impact factor: 3.989